Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 20Ureteral Neoplasms 7Urologic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Urogenital Neoplasms 2Urethral Neoplasms 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 119Cisplatin 33lenvatinib 29Carboplatin 28Paclitaxel 27Docetaxel 14Pemetrexed 13Fluorouracil 12Capecitabine 11Saline Solution 10Oxaliplatin 10Gemcitabine 10Albumin-Bound Paclitaxel 7olaparib 6Leucovorin 6Bevacizumab 6epacadostat 5belzutifan 5Etoposide 5Cetuximab 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enzalutamide 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3Radiotherapy 3Levoleucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × enfortumab vedotin × 1 year × Clear all
NCT06483334 2026-02-18

MK-3475-04C

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
38 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04700124 2026-02-05

KEYNOTE-B15

Merck Sharp & Dohme LLC

Phase 3 Completed
808 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT06305767 2026-01-13

INTerpath-005

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
230 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡